Answers are grounded in this paper and cite their sources.
Relying on the proposed gut–bone marrow bidirectional regulatory axis, the gut microbiota may influence systemic immune homeostasis and the bone marrow hematopoietic microenvironment through maintenance of the mucosal barrier and signaling molecules such as short-chain fatty acids and tryptophan metabolites, and may thereby contribute to the pathobiology of hematological malignancies. Patients with hematological malignancies often exhibit dysbiosis, including decreased gut microbial diversity, the depletion of butyrate-producing beneficial bacteria, and the overproliferation of opportunistic pathogens, although patterns vary across cohorts. This dysbiosis may contribute to malignant clonal expansion and disease progression and has been associated with variation in the response to chemotherapy and cellular therapy and with the risk of graft-versus-host disease, severe infections, and intestinal mucositis following allogeneic hematopoietic stem cell transplantation. This narrative review summarizes interactions between the gut microbiota and hematological malignancies, disease-associated microbiota profiles, treatment-related associations, and barriers to clinical translation. Because much of the human evidence is observational, microbiota-directed interventions require prospective validation before routine clinical use.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: